Showing results (101-110 of 145) with videos related to
Sort By:
Pageof 15
Dermatology and Therapy|March 4, 2021
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot StudyUlrich Mrowietz, A David Burden, Andreas Pinter, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|February 9, 2024
Psychometric validation of the Psoriasis Symptom Scale, Functional Assessment of Chronic Illness Therapy-Fatigue and pain-Visual Analogue Scale in patients with generalized pustular psoriasisA David Burden, Robert Bissonnette, Milena Anatchkova, et al.Dermatology and Therapy|November 5, 2022
Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular PsoriasisAkimichi Morita, Siew Eng Choon, Hervé Bachelez, et al.Trials|August 31, 2018
A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trialVictoria Cornelius, Rosemary Wilson, Suzie Cro, et al.The Journal of Investigative Dermatology|August 30, 2016
Spread of Psoriasiform Inflammation to Remote Tissues Is Restricted by the Atypical Chemokine Receptor ACKR2Kave Shams, Gillian J Wilson, Mark Singh, et al.American Journal of Human Genetics|July 31, 2002
Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locusColin D Veal, Francesca Capon, Michael H Allen, et al.The Journal of Investigative Dermatology|January 19, 2005
The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasisMichael Hugh Allen, Hahreen Ameen, Colin Veal, et al.JAMA Dermatology|March 29, 2018
Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIRKayleigh J Mason, Jonathan N W N Barker, Catherine H Smith, et al.The Journal of Investigative Dermatology|July 14, 2024
Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1Ahmed Farag, Sudha Visvanathan, Hervé Bachelez, et al.Human Genetics|June 26, 2007
Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasisFrancesca Capon, Paola Di Meglio, Joanna Szaub, et al.Pageof 15